ELTP - Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty generic drug manufacturer focused on abuse-deterrent extended-release opioid formulations, including its proprietary SequestOx abuse-deterrent technology platform and FDA-approved generic analgesics such as oxycodone ER. The company operates a hybrid model combining its own branded generic pharmaceutical sales to drug wholesalers and retail pharmacies with contract development and manufacturing (CDMO) services for other pharmaceutical companies. Revenue is sub-$30M annually, with operations concentrated entirely in the United States market and manufacturing based in Northvale, New Jersey. The company is a micro-cap with a thin product portfolio heavily exposed to opioid regulatory risk and dependent on a small number of CDMO clients for a significant portion of revenue.

Past Year Trends

• Elite Pharmaceuticals grew full-year FY2025 revenue to $84.0 million, a 48% increase from $56.6 million in FY2024, driven primarily by new generic product launches across its controlled-substance ANDA portfolio. (Bullish)
• Elite received FDA approval on November 18, 2024, for generic Lisdexamfetamine Dimesylate (generic Vyvanse) in 7 strengths and commercially launched in December 2024, capturing approximately 8% market share in a branded market with $4.3 billion in annual U.S. sales. (Bullish)
• Q3 FY2025 (ended December 31, 2024) operating profit collapsed 69% year-over-year to $1.1 million as December holiday-period shipping delays deferred product revenue, exposing the company's vulnerability to timing-driven revenue volatility. (Bearish)

Next Year Trends

• Elite launched generic Oxycodone/Acetaminophen (generic Percocet) in April 2025 across three strengths targeting a $317 million annual U.S. market; commercial uptake and distribution agreement performance will be the primary revenue catalyst for FY2026. (Bullish)
• Generic Vyvanse faces quota-based competition from multiple DEA-licensed manufacturers, which is expected to compress Elite's ~8% market share and erode per-unit margins on its highest-revenue product through the next 12 months. (Bearish)
• FDA approval of generic Ropinirole XL (Requip XL equivalent) in November 2025 across five strengths adds a non-controlled CNS product to Elite's launch pipeline, providing incremental revenue diversification away from Schedule II controlled substances. (Bullish)

Red Flags

No severe red flags identified as of August 2025.